Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Curr Psychiatry Rep. 2013 Nov;15(11):10.1007/s11920-013-0415-y. doi: 10.1007/s11920-013-0415-y

Table 2.

Medications assessed for cocaine and METH/AMPH use disorders

Substance Medication Target Action
Cocaine Disulfiram
Doxazosin
Modafinil
Topiramate
Methylphenidate
SR-METH/AMPH
Dopamine β-hydroxylase
α1 receptors
DAT, α receptors
AMPA/Kainate, GABA
NET, DAT
NET, DAT
↓ NE, ↑ DA
↓ cocaine-induced DA
↑ DA, Glutamate, Orexin, ↓ GABA
↓ Glutamate, ↑ GABA
↑ NE, ↑ DA
↑ NE, ↑ DA
METH/AMPH Bupropion
Naltrexone
Rivastigmine
Topiramate
Perindopril
Modafinil
Methylphenidate
DAT, NET
μ opioid receptors
Acetylcholinesterase
AMPA/Kainate, GABA
ACE
DAT, α receptors
NET, DAT
↑ DA, ↑ NE
↓ μ receptor activation
↑ acetylcholine
↓ Glutamate, ↑ GABA
↑ DA, ↓ NE
↑ DA, Glutamate, Orexin, ↓ GABA
↑ NE ↑ DA

AMPA-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, ACE-angiotensin converting enzyme, DA-dopamine, NE-norepinephrine, GABA-γ aminobutyric acid, DAT-dopamine transporter, NET-norepinephrine transporter, SR-METH-sustained release methamphetamine, SR-AMPH-sustained release amphetamine.